Exondys 51

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are tanking Tuesday morning as a binary event turned up a negative outcome for the company. What Happened Sarepta announced Monday after the market close the FDA issued a complete response letter for its NDA seeking accelerated approval for...

Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded the following: Sarepta Therapeutics Inc (NASDAQ: SRPT) from Overweight to Sector Weight...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 1 percent on Thursday after the company reported its third consecutive beat and raise earnings report, analysts at Cowen said in a research report. The firm's Ritu Baral,/a> maintains an Outperform rating on Sarepta's stock with an...

Analysts at Morgan Stanley conducted a tracking survey to gain a better understanding of Sarepta Therapeutics Inc (NASDAQ: SRPT)'s outlook for its Exondys 51 therapy. After coming away with encouraging data, the firm's David Lebowitz upgraded Sarepta's stock rating from Equal Weight to Overweight...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) gained more than 13 percent Friday after the FDA found that the company's experimental drug to treat Duchenne muscular dystrophy may work. The FDA's Advisory Committee meeting ruled that the body of evidence for the company's ataluren...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared by more than 10 percent Wednesday after the company reported encouraging results from a clinical trial of a therapy intended to treat Duchenne muscular dystrophy (DMD). Sarepta's drug called golodirsen showed that patients who suffer from...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a smid-cap biopharmaceutical company that focuses on the treatment of rare neuromuscular diseases including Duchenne muscular dystrophy, saw its stock peak north of $60 per share in late 2016 after the U.S. Food and Drug Administration green-lighted its DMD...

Even as it recovered from poor fourth-quarter results, Capricor Therapeutics Inc (NASDAQ: CAPR) pumped a little hope into the world of Duchenne muscular dystrophy last week with positive clinical results from its CAP-1002 study. And the breadth of impact could ultimately be more expansive. “...

Sarepta Therapeutics Inc (NASDAQ: SRPT) was trading higher Friday after a Thursday-night update of Exondys 51 annual sales guidance from $80 million to $95 million. The figure still fell short of Oppenheimer’s $100 million estimate — and analyst Hartaj Singh even considers his rate...

Sarepta Therapeutics Inc (NASDAQ: SRPT) presented encouraging long-term cardiac and pulmonary data at the MDA Scientific Conference. The data could provide “additional support for the clinical benefit from Exondys 51 treatment,” SunTrust Robinson Humphrey’s Edward Nash said in a...

Sarepta Therapeutics Inc's (NYSE: SRPT) rough Tuesday carried over into Wednesday's session after the company reported a better than expected loss in its fourth quarter but expects full year sales of Exondys to fall short of what analysts were expecting. Brian Skorney of Baird commented in...

Shares of Sarepta Therapeutics Inc (NASDAQ: SPRT) were under heavy selling pressure following a concerning report released by Leerink's Joseph Schwartz. Schwartz completed a MEDACorp payor survey and the results suggest the reimbursement landscape for Sarepta's therapy for the treatment...

It has been more than three decades since the U.S. Congress passed a bill encouraging pharmaceutical companies to develop new drugs to treat rare diseases. According to NPR, President Ronald Reagan's Orphan Drug Act of 1983 resulted in more than 200 companies introducing 450 orphan drugs to the...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 23 percent on Tuesday after the company reported positive numbers on recently-approved Duchenne muscular dystrophy (DMD) drug Exondys 51 at the JPMorgan Healthcare Conference. The company reported that Exondys 51 saw sales of $5.4...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by more than 24 percent Tuesday. The catalyst for the move appears to be the company's 10:30 a.m. presentation at the JPMorgan Healthcare Conference, followed by an encouraging report by TheStreet's Adam Feuerstein. As...